[go: up one dir, main page]

ES2162561B1 - PHARMACEUTICAL COMPOSITION OF ORAL, LIQUID, TRANSPARENT, STABLE AND ACCEPTABLE FLAVOR METAMIZOL. - Google Patents

PHARMACEUTICAL COMPOSITION OF ORAL, LIQUID, TRANSPARENT, STABLE AND ACCEPTABLE FLAVOR METAMIZOL.

Info

Publication number
ES2162561B1
ES2162561B1 ES9901431A ES9901431A ES2162561B1 ES 2162561 B1 ES2162561 B1 ES 2162561B1 ES 9901431 A ES9901431 A ES 9901431A ES 9901431 A ES9901431 A ES 9901431A ES 2162561 B1 ES2162561 B1 ES 2162561B1
Authority
ES
Spain
Prior art keywords
metamizol
oral
transparent
stable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES9901431A
Other languages
Spanish (es)
Other versions
ES2162561A1 (en
Inventor
De Vidal Marta Noemi Cicconi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Espana SA
Original Assignee
Boehringer Ingelheim Espana SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Espana SA filed Critical Boehringer Ingelheim Espana SA
Priority to ES9901431A priority Critical patent/ES2162561B1/en
Publication of ES2162561A1 publication Critical patent/ES2162561A1/en
Application granted granted Critical
Publication of ES2162561B1 publication Critical patent/ES2162561B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición farmacéutica de metamizol oral, líquida, transparente, estable y de sabor aceptable. Para 10 ml comprende: a) entre 1 y 3 g de metamizol magnésico, preferiblemente 2 g, como principio activo; b) entre 0,01 y 0,15 g de mentol, preferiblemente entre 0,02 y 0,06 g, como correctivo del sabor; c) la cantidad suficiente de un agente conservante, que preferiblemente es entre 1 y 2 g de propilenglicol; d) la cantidad suficiente de una mezcla sorbitol: agua cuya proporción relativa en peso está entre 1:1 y 1:1,5, como vehículo y correctivo del sabor; e) entre 0,5 y 1,5 g de glicerina, como vehículo y correctivo del sabor; y f) entre 0,005 y 0,1 g de sacarina sódica. No es de ingestión desagradable, directamente o tras su dilución en agua, resultando útil para la administración de metamizol a niños, ancianos y pacientes poco motivados o con dificultades para tragar.Pharmaceutical composition of oral metamizol, liquid, transparent, stable and of acceptable flavor. For 10 ml it comprises: a) between 1 and 3 g of magnesium metamizol, preferably 2 g, as active ingredient; b) between 0.01 and 0.15 g of menthol, preferably between 0.02 and 0.06 g, as a flavor corrective; c) the sufficient amount of a preservative agent, which is preferably between 1 and 2 g of propylene glycol; d) the sufficient amount of a sorbitol: water mixture whose relative weight ratio is between 1: 1 and 1: 1.5, as a vehicle and corrective taste; e) between 0.5 and 1.5 g of glycerin, as a vehicle and flavor corrective; and f) between 0.005 and 0.1 g of sodium saccharin. It is not of unpleasant ingestion, directly or after its dilution in water, being useful for the administration of metamizol to children, elderly and patients with little motivation or difficulty swallowing.

ES9901431A 1999-06-28 1999-06-28 PHARMACEUTICAL COMPOSITION OF ORAL, LIQUID, TRANSPARENT, STABLE AND ACCEPTABLE FLAVOR METAMIZOL. Expired - Lifetime ES2162561B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9901431A ES2162561B1 (en) 1999-06-28 1999-06-28 PHARMACEUTICAL COMPOSITION OF ORAL, LIQUID, TRANSPARENT, STABLE AND ACCEPTABLE FLAVOR METAMIZOL.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9901431A ES2162561B1 (en) 1999-06-28 1999-06-28 PHARMACEUTICAL COMPOSITION OF ORAL, LIQUID, TRANSPARENT, STABLE AND ACCEPTABLE FLAVOR METAMIZOL.

Publications (2)

Publication Number Publication Date
ES2162561A1 ES2162561A1 (en) 2001-12-16
ES2162561B1 true ES2162561B1 (en) 2002-07-16

Family

ID=8309001

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9901431A Expired - Lifetime ES2162561B1 (en) 1999-06-28 1999-06-28 PHARMACEUTICAL COMPOSITION OF ORAL, LIQUID, TRANSPARENT, STABLE AND ACCEPTABLE FLAVOR METAMIZOL.

Country Status (1)

Country Link
ES (1) ES2162561B1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600708A (en) * 1985-07-19 1986-07-15 American Home Products Corporation Propranolol hydrochloride liquid formulations
JPH06100602A (en) * 1992-09-18 1994-04-12 Asahi Chem Ind Co Ltd Solid oral preparation and production thereof
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
JPH10273435A (en) * 1997-01-29 1998-10-13 Fujisawa Pharmaceut Co Ltd Internal liquid preparation

Also Published As

Publication number Publication date
ES2162561A1 (en) 2001-12-16

Similar Documents

Publication Publication Date Title
ES2312585T3 (en) THERAPY AGAINST MIGRAINE VIA VIA TOPICA.
Lin et al. Sulfur revisited
AU2010219295B2 (en) Oleaginous pharmaceutical and cosmetic foam
ES2828711T3 (en) Peroxide formulations and methods and applicators to use them
JP5841151B2 (en) Nasal spray
ES2180646T3 (en) ORAL LIQUID FORMULATIONS OF ALENDRONATE.
UA79196C2 (en) Intranasal formulation of rotigotine
ES2314304T3 (en) TOPIC PHARMACEUTICAL COMPOSITIONS CONTAINING PROPER NATURAL ACTIVE PRINCIPLES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY PROCESSES OF MUCOSES.
AR073793A1 (en) PHARMACEUTICAL FORMULATION LIQUID CONTAINING PARACETAMOL. EXCIPIENT LIQUID
JP2001302518A (en) Method for improving action and agent for improving action
ES2707775T3 (en) Composition containing hesperidin
ES2171440T3 (en) SOLID COMPOSITION MUCOADHESIVA, THERAPEUTICS OR HYGIENIC, FOR ADMINISTRATION BY APPLICATION ON THE MUCOSA ORAL OR NASAL.
ES2212550T3 (en) ORAL LIQUID SOLUTION UNDERSTANDING THE MIRTAZAPINE ANTIDEPRESSOR.
ES2383433T3 (en) Pharmaceutical formulation of apomorphine for oral administration
In Salicylic acid
KR20040084944A (en) Ambroxol for treating painful conditions in the mouth and pharyngeal cavity
IE60241B1 (en) Antitussive liquid compositions containing phenol
JP2003128583A (en) Refreshing composition
ES2162561B1 (en) PHARMACEUTICAL COMPOSITION OF ORAL, LIQUID, TRANSPARENT, STABLE AND ACCEPTABLE FLAVOR METAMIZOL.
ES2942361T3 (en) Methods and compositions for soft anticholinergic esters
PT1711162T (en) COMPOSITION FOR USE IN THE LOCAL TREATMENT OF OROFARINGEAL AFFECTIONS COMPARING IBUPROFEN OR CETOPROFENE
TR201909422T4 (en) Oral topical aqueous pharmaceutical compositions of flurbiprofen and dexpanthenol.
JP2001302545A (en) Refreshing agent
ES2215025T3 (en) EFERVESCENT PHARMACEUTICAL FORMULATION, CONTAINING METAMIZOL.
MX2022007504A (en) Liquid composition comprising ibuprofen and phenylephrine.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20011216

Kind code of ref document: A1

Effective date: 20011216